Skip to main content

Advertisement

Log in

Total peroxiredoxin expression is associated with survival in patients with follicular lymphoma

  • Original Article
  • Published:
Virchows Archiv Aims and scope Submit manuscript

Abstract

Redox state-regulating enzymes may have roles in chemoresistance and also in lymphomagenesis, but there have been only a limited number of studies on this topic in lymphomas. Our aim was to assess expression of the redox state-regulating enzymes peroxiredoxins (Prxs) I–VI and thioredoxin (Trx) and the oxidative stress marker nitrotyrosine in follicular lymphomas (FLs). We immunohistochemically assessed Prxs I–VI, Trx and nitrotyrosine in a cohort of 76 histologically confirmed, untreated FLs. We also studied the localisation of Prxs I, II, III, V and VI by means of immunoelectron microscopy (IEM). Immunohistochemistry results were correlated with disease-specific survival (DSS), progression-free survival (PFS), overall survival (OS) and clinical prognostic factors. When all Prx expression intensities were grouped as a single variable, we discovered that high total Prx intensity correlated with favourable DSS (p = 0.024) and OS (p = 0.035) but not with PFS. No deaths due to lymphoma were recorded amongst patients with high total Prx expression during the median follow-up period of 7.6 years. IEM results were in line with earlier ones demonstrating wide subcellular localisation of Prx isoenzymes. In conclusion, our results demonstrate an association between high total Prx expression and prolonged survival and suggest that Prxs may have a protective role in FL that cannot be compensated by other antioxidant mechanisms.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Nooka AK, Nabhan C, Zhou X, Taylor MD, Byrtek M, Miller TP, Friedberg JW, Zelenetz AD, Link BK, Cerhan JR, Dillon H, Sinha R, Shenoy PJ, Levy D, Dawson K, Hirata JH, Flowers CR (2013) Examination of the Follicular Lymphoma International Prognostic Index (FLIPI) in the National LymphoCare Study (NLCS): a prospective US patient cohort treated predominantly in community practices. Ann Oncol. doi:10.1093/annonc/mds429

    PubMed  Google Scholar 

  2. Yamamoto E, Tomita N, Sakata S, Tsuyama N, Takeuchi K, Nakajima Y, Miyashita K, Tachibana T, Takasaki H, Tanaka M, Hashimoto C, Koharazawa H, Fujimaki K, Taguchi J, Harano H, Motomura S, Ishigatsubo Y (2013) MIB-1 labeling index as a prognostic factor for patients with follicular lymphoma treated with rituximab plus CHOP therapy. Cancer Sci. doi:10.1111/cas.12288

    Google Scholar 

  3. Wood B, Sikdar S, Choi SJ, Virk S, Alhejaily A, Baetz T, LeBrun DP (2013) Abundant expression of interleukin-21 receptor in follicular lymphoma cells is associated with more aggressive disease. Leuk Lymphoma. doi:10.3109/10428194.2012.742522

    PubMed  Google Scholar 

  4. Li YJ, Jiang WQ, Rao HL, Huang JJ, Xia Y, Huang HQ, Lin TY, Xia ZJ, Li S, Li ZM (2012) Expression of BAFF and BAFF-R in follicular lymphoma: correlation with clinicopathologic characteristics and survival outcomes. PLoS ONE. doi:10.1371/journal.pone.0050936

    Google Scholar 

  5. Collins Y, Chouchani ET, James AM, Menger KE, Cocheme HM, Murphy MP (2012) Mitochondrial redox signalling at a glance. J Cell Sci. doi:10.1242/jcs.098475

    PubMed  Google Scholar 

  6. Rhee SG, Woo HA, Kil IS, Bae SH (2012) Peroxiredoxin functions as a peroxidase and a regulator and sensor of local peroxides. J Biol Chem. doi:10.1074/jbc.R111.283432

    Google Scholar 

  7. Kinnula VL, Lehtonen S, Sormunen R, Kaarteenaho-Wiik R, Kang SW, Rhee SG, Soini Y (2002) Overexpression of peroxiredoxins I, II, III, V, and VI in malignant mesothelioma. J Pathol 196:316–323

    Article  CAS  PubMed  Google Scholar 

  8. Ren P, Ye H, Dai L, Liu M, Liu X, Chai Y, Shao Q, Li Y, Lei N, Peng B, Yao W, Zhang J (2013) Peroxiredoxin 1 is a tumor-associated antigen in esophageal squamous cell carcinoma. Oncol Rep. doi:10.3892/or. 2013.2714

    PubMed Central  Google Scholar 

  9. Lu W, Fu Z, Wang H, Feng J, Wei J, Guo J (2014) Peroxiredoxin 2 is upregulated in colorectal cancer and contributes to colorectal cancer cells’ survival by protecting cells from oxidative stress. Mol Cell Biochem 387(1–2):261–270

    Article  CAS  PubMed  Google Scholar 

  10. Demasi AP, Martinez EF, Napimoga MH, Freitas LL, Vassallo J, Duarte AS, Soares AB, Araujo NS, Araujo VC (2013) Expression of peroxiredoxins I and IV in multiple myeloma: association with immunoglobulin accumulation. Virchows Arch. doi:10.1007/s00428-013-1433-1

    PubMed  Google Scholar 

  11. Bur H, Haapasaari KM, Turpeenniemi-Hujanen T, Kuittinen O, Auvinen P, Marin K, Koivunen P, Sormunen R, Soini Y, Karihtala P (2014) Oxidative stress markers and mitochondrial antioxidant enzyme expression are increased in aggressive Hodgkin lymphomas. Histopathology 65:319–327

    Article  PubMed  Google Scholar 

  12. Kuusisto ME, Haapasaari KM, Turpeenniemi-Hujanen T, Jantunen E, Soini Y, Peroja P, Bloigu R, Karihtala P, Kuittinen O (2015) High intensity of cytoplasmic peroxiredoxin VI expression is associated with adverse outcome in diffuse large B-cell lymphoma independently of international prognostic index. J Clin Pathol 68:552–556

    Article  CAS  PubMed  Google Scholar 

  13. Murata M, Kawanishi S (2004) Oxidative DNA damage induced by nitrotyrosine, a biomarker of inflammation. Biochem Biophys Res Commun 316:123–128

    Article  CAS  PubMed  Google Scholar 

  14. Peroja P, Pasanen AK, Haapasaari KM, Jantunen E, Soini Y, Turpeenniemi-Hujanen T, Bloigu R, Lilja L, Kuittinen O, Karihtala P (2012) Oxidative stress and redox state-regulating enzymes have prognostic relevance in diffuse large B-cell lymphoma. Exp Hematol Oncol 1:2–3619-1-2

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Pasanen AK, Kuitunen H, Haapasaari KM, Karihtala P, Kyllonen H, Soini Y, Turpeenniemi-Hujanen T, Kuittinen O (2012) Expression and prognostic evaluation of oxidative stress markers in an immunohistochemical study of B-cell derived lymphomas. Leuk Lymphoma. doi:10.3109/10428194.2011.624226

    PubMed  Google Scholar 

  16. Slot JW, Geuze HJ (1985) A new method of preparing gold probes for multiple-labeling cytochemistry. Eur J Cell Biol 38:87–93

    CAS  PubMed  Google Scholar 

  17. Rani V, Neumann CA, Shao C, Tischfield JA (2012) Prdx1 deficiency in mice promotes tissue specific loss of heterozygosity mediated by deficiency in DNA repair and increased oxidative stress. Mutat Res 735:39–45

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Cao J, Schulte J, Knight A, Leslie NR, Zagozdzon A, Bronson R, Manevich Y, Beeson C, Neumann CA (2009) Prdx1 inhibits tumorigenesis via regulating PTEN/AKT activity. EMBO J. doi:10.1038/emboj.2009.101

    Google Scholar 

  19. Han YH, Kim HS, Kim JM, Kim SK, Yu DY, Moon EY (2005) Inhibitory role of peroxiredoxin II (Prx II) on cellular senescence. FEBS Lett 579:4897–4902

    Article  CAS  PubMed  Google Scholar 

  20. Kubota D, Mukaihara K, Yoshida A, Tsuda H, Kawai A, Kondo T (2013) Proteomics study of open biopsy samples identifies peroxiredoxin 2 as a predictive biomarker of response to induction chemotherapy in osteosarcoma. J Proteome. doi:10.1016/j.jprot.2013.07.022

    Google Scholar 

  21. Suenaga S, Kuramitsu Y, Wang Y, Baron B, Kitagawa T, Akada J, Tokuda K, Kaino S, Maehara S, Maehara Y, Sakaida I, Nakamura K (2013) Human pancreatic cancer cells with acquired gemcitabine resistance exhibit significant up-regulation of peroxiredoxin-2 compared to sensitive parental cells. Anticancer Res 33(11):4821–4826

    CAS  PubMed  Google Scholar 

  22. Sun QK, Zhu JY, Wang W, Lv Y, Zhou HC, Yu JH, Xu GL, Ma JL, Zhong W, Jia WD (2014) Diagnostic and prognostic significance of peroxiredoxin 1 expression in human hepatocellular carcinoma. Med Oncol. doi:10.1007/s12032-013-0786-2

    Google Scholar 

  23. Kalinina EV, Berezov TT, Shtil’ AA, Chernov NN, Glazunova VA, Novichkova MD, Nurmuradov NK (2012) Expression of peroxiredoxin 1, 2, 3, and 6 genes in cancer cells during drug resistance formation. Bull Exp Biol Med 153(6):879–882

    Article  CAS  Google Scholar 

  24. He T, Banach-Latapy A, Vernis L, Dardalhon M, Chanet R, Huang ME (2013) Peroxiredoxin 1 knockdown potentiates beta-lapachone cytotoxicity through modulation of reactive oxygen species and mitogen-activated protein kinase signals. Carcinogenesis. doi:10.1093/carcin/bgs389

    Google Scholar 

  25. Jing L, Wu Y, Wu J, Zhao J, Zuo D, Peng S (2011) Peroxiredoxins are involved in metallothionein protection from doxorubicin cardiotoxicity. Eur J Pharmacol. doi:10.1016/j.ejphar.2011.03.031

    Google Scholar 

  26. Nicolussi A, D’Inzeo S, Mincione G, Buffone A, Di Marcantonio MC, Cotellese R, Cichella A, Capalbo C, Di Gioia C, Nardi F, Giannini G, Coppa A (2014) PRDX1 and PRDX6 are repressed in papillary thyroid carcinomas via BRAF V600E-dependent and -independent mechanisms. Int J Oncol. doi:10.3892/ijo.2013.2208

    PubMed  Google Scholar 

Download references

Acknowledgments

We would like extend our gratitude to Anne Bisi for her skilful assistance with staining. We thank Biocenter Oulu Electron Microscopy Laboratory personnel for the preparation of samples for immunoelectron microscopy.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Pekka Peroja.

Ethics declarations

The Ethics Committee of the Northern Ostrobothnia Hospital District approved the study design and is in concordance with the Helsinki declaration.

Conflict of interest

Authors declare no conflict of interest.

Contributions

PP, KMH, MLKL, PKa, SM, IM, PKo and SL performed the research; PP, PKa, OK, MELK and TTH designed the research study; TTH and PKo contributed essential reagents or tools; PP, OK and PKa analysed the data; and PP, OK and Pka wrote the paper.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Peroja, P., Haapasaari, KM., Mannisto, S. et al. Total peroxiredoxin expression is associated with survival in patients with follicular lymphoma. Virchows Arch 468, 623–630 (2016). https://doi.org/10.1007/s00428-016-1920-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00428-016-1920-2

Keywords

Navigation